Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool

Urologic Oncology: Seminars and Original Investigations

Volumn 36, Issue 5, 2018, Pages 239.e1-239.e7

  D′Andrea, David ^a   Abufaraj, Mohammad ^a,b   Susani, Martin ^a   Ristl, Robin ^a   Foerster, Beat ^a,c   Kimura, Shoji ^a,d   Mari, Andrea ^a   Soria, Francesco ^a   Briganti, Alberto ^e   Karakiewicz, Pierre I ^f   Gust, Killian M ^a   Rouprêt, Morgan ^g   Shariat, Shahrokh F ^a,h,i,j  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JORDAN UNIVERSITY HOSPITAL   (Jordan)

^c CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h Karl Landsteiner Institute   (Austria)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

Lymphovascular invasion; Prognosis; Progression; Urothelial bladder cancer; Variant histology

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER SURGERY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL DECISION MAKING; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NOMOGRAM; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR VOLUME; UROTHELIAL BLADDER CANCER; BLADDER TUMOR; CANCER STAGING; MIDDLE AGED; MUSCLE TUMOR; PATHOLOGY; PREVENTION AND CONTROL; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE;

AGED; CLINICAL DECISION-MAKING; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 85042653780     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2018.01.018     Document Type: Article

References (29)

1. Gontero, P., Sylvester, R., Pisano, F., Joniau, S., Vander Eeckt, K., Serretta, V., et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67 (2015), 74–82, 10.1016/j.eururo.2014.06.040.
2. Cambier, S., Sylvester, R.J., Collette, L., Gontero, P., Brausi, M.A., van Andel, G., et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin. Eur Urol 69 (2016), 60–69, 10.1016/j.eururo.2015.06.045.
3. van den Bosch, S., Alfred Witjes, J., Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60 (2011), 493–500, 10.1016/j.eururo.2011.05.045.
4. Sylvester, R.J., van der Meijden, A.P.M., Oosterlinck, W., Witjes, J.A., Bouffioux, C., Denis, L., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. [466–5–discussion475–7] Eur Urol, 49, 2006, 10.1016/j.eururo.2005.12.031.
5. Fernandez-Gomez, J., Madero, R., Solsona, E., Unda, M., Martinez-Piñeiro, L., Gonzalez, M., et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182 (2009), 2195–2203, 10.1016/j.juro.2009.07.016.
6. Babjuk, M., Böhle, A., Burger, M., Capoun, O., Cohen, D., Compérat, E.M., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71 (2017), 447–461, 10.1016/j.eururo.2016.05.041.
7. Fernandez-Gomez, J., Madero, R., Solsona, E., Unda, M., Martinez-Piñeiro, L., Ojea, A., et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol 60 (2011), 423–430, 10.1016/j.eururo.2011.05.033.
8. Xylinas, E., Kent, M., Kluth, L., Pycha, A., Comploj, E., Svatek, R.S., et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 109 (2013), 1460–1466, 10.1038/bjc.2013.372.
9. Shariat, S.F., Margulis, V., Lotan, Y., Montorsi, F., Karakiewicz, P.I., Nomograms for bladder cancer. Eur Urol 54 (2008), 41–53, 10.1016/j.eururo.2008.01.004.
10. Kamat, A.M., Gee, J.R., Dinney, C.P.N., Grossman, H.B., Swanson, D.A., Millikan, R.E., et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175 (2006), 881–885, 10.1016/S0022-5347(05)00423-4.
11. Wright, J.L., Black, P.C., Brown, G.A., Porter, M.P., Kamat, A.M., Dinney, C.P., et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. [discussion2307] J Urol 178 (2007), 2302–2306, 10.1016/j.juro.2007.08.038.
12. Willis, D.L., Fernández, M.I., Dickstein, R.J., Parikh, S., Shah, J.B., Pisters, L.L., et al. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol 193 (2015), 1129–1134, 10.1016/j.juro.2014.09.092.
13. Shapur, N.K., Katz, R., Pode, D., Shapiro, A., Yutkin, V., Pizov, G., et al. Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors, 3, 2011, e22, 10.4081/rt.2011.e22.
14. Streeper, N.M., Simons, C.M., Konety, B.R., Muirhead, D.M., Williams, R.D., O'Donnell, M.A., et al. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int 103 (2009), 475–479, 10.1111/j.1464-410X.2008.08011.x.
15. Martin-Doyle, W., Leow, J.J., Orsola, A., Chang, S.L., Bellmunt, J., Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol, 33, 2015, 10.1200/JCO.2014.57.6967.
16. Tilki, D., Shariat, S.F., Lotan, Y., Rink, M., Karakiewicz, P.I., Schoenberg, M.P., et al. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int 111 (2013), 1215–1221, 10.1111/j.1464-410X.2012.11455.x.
17. Mathieu, R., Lucca, I., Rouprêt, M., Briganti, A., Shariat, S.F., The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol 13 (2016), 471–479, 10.1038/nrurol.2016.126.
18. Shariat, S.F., Svatek, R.S., Tilki, D., Skinner, E., Karakiewicz, P.I., Capitanio, U., et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105 (2010), 1402–1412, 10.1111/j.1464-410X.2010.09217.x.
19. Moch, H., Humphrey, P.A., Ulbright, T.M., Reueter, V.E., Fouth edition WHO Classification of Tumours of the Urinary System and Male Genital Organs, 2016, 2016, International Agency for Research on Cancer, Lyon, France.
20. Rink, M., Fajkovic, H., Cha, E.K., Gupta, A., Karakiewicz, P.I., Chun, F.K., et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61 (2012), 854–855, 10.1016/j.eururo.2011.12.055.
21. Xylinas, E., Kent, M., Kluth, L., Pycha, A., Comploj, E., Svatek, R.S., et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 109 (2013), 1460–1466.
22. Kim, H.S., Kim, M., Jeong, C.W., Kwak, C., Kim, H.H., Ku, J.H., Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis. Urol Oncol 32 (2014), 1191–1199, 10.1016/j.urolonc.2014.05.008.
23. Badalato, G.M., Gaya, J.M., Hruby, G., Patel, T., Kates, M., Sadeghi, N., et al. Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference?. BJU Int 110 (2012), 1471–1477, 10.1111/j.1464-410X.2012.11116.x.
24. Fritsche, H.-M., Burger, M., Svatek, R.S., Jeldres, C., Karakiewicz, P.I., Novara, G., et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57 (2010), 300–309, 10.1016/j.eururo.2009.09.024.
25. Moschini, M., D'Andrea, D., Korn, S., Irmak, Y., Soria, F., Compérat, E., et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 14 (2017), 651–668, 10.1038/nrurol.2017.125.
26. Babjuk, M., Palou, J., Zigeuner, R., Capoun, O., Burger, M., Böhle, A., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:3 (2016), 447–461 http://dx.doi.org/10.1016/j.eururo.2016.05.041.
27. Wasco, M.J., Daignault, S., Zhang, Y., Kunju, L.P., Kinnaman, M., Braun, T., et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 70 (2007), 69–74, 10.1016/j.urology.2007.03.033.
28. Cai, T., Tiscione, D., Verze, P., Pomara, G., Racioppi, M., Nesi, G., et al. Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens. Urology 84 (2014), 1141–1146, 10.1016/j.urology.2014.06.032.
29. Gofrit, O.N., Yutkin, V., Shapiro, A., Pizov, G., Zorn, K.C., Hidas, G., et al. The response of variant histology bladder cancer to intravesical immunotherapy compared to conventional cancer. Front Oncol, 6, 2016, 43, 10.3389/fonc.2016.00043.